Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer

Video

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

John Longshore, PhD, FACMG, director, Molecular Pathology, Carolinas Pathology Group, Atrium Health, discusses key molecular markers in metastatic lung cancer.

The National Comprehensive Cancer Network guidelines recommend broad molecular testing. Genes that could harbor potentially actionable mutations and should be tested include EGFR, ALK, ROS1, BRAF, NTRK, HER2, MET exon 14 skipping, RET, and KRAS G12C. Additionally, tumor mutational burden should be profiled, says Longshore.

Despite the wealth of actionable targets in the metastatic setting, EGFR mutations are the only indicated molecular marker for early-stage disease based on the data from the phase 3 ADAURA trial, concludes Longshore.

Related Videos
John Shen, MD
Tatyana Feldman, MD
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine